LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr.
… efficacy endpoints. “QR-010 has the potential to be an innovative RNA therapy for patients with CF due to the … from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. About …